RICHMOND, Calif., Oct. 10, 2017 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. EKSO, an industry leader in exoskeleton technology for medical and industrial use, today announced that the company will showcase the latest features of the EksoGT™ wearable exoskeleton at the 2017 American Academy of Physical Medicine and Rehabilitation (AAPM&R) Annual Assembly taking place October 12-15, 2017, in Denver, CO. For the first time at AAPM&R, attendees can learn how SmartAssist™ and EksoPulse™ technology can help them provide advanced personalized patient care.
Live demonstrations of the EksoGT™, the first and only exoskeleton cleared by the FDA for stroke and spinal cord rehabilitation, will take place at booth #200. Clinicians will be able to explore the technology firsthand, learn about the clinical benefits, and engage with Company experts on exoskeleton rehabilitation. The booth will also display a new video series highlighting the experiences of patients and clinicians.
On Friday, October 13, Ekso Bionics will also be hosting a Meet and Greet from 2:00 – 5:00 p.m. MT at their booth, where attendees can connect with experts who are experienced with using the EksoGT™ for stroke and spinal cord injury rehabilitation.
The EksoGT™ enables individuals to stand up and walk with a full weight bearing, reciprocal gait. The device amplifies patient's natural abilities and is designed to help them get back on their feet earlier by aiding their re-learning of correct step patterns and weight shifting.
The SmartAssist™ technology is the next generation gait therapy software, allows physical therapy to vary the support of the device for each leg independently – from full power to free walking – and thereby offers personalized therapy specific to the needs of a larger range of patients. EksoPulse™ is an advanced cloud-based technology for physical therapists to obtain insights in rehabilitation to capture patient progress and allows further personalization of care in real-time.
AAPM&R is the foremost medical society for the specialty of physical medicine and rehabilitation. More than 3,000 physiatrists from around the world are expected to attend the Annual Assembly for educational sessions, networking events, and research aimed at the diverse clinical and practice interest of today's physiatrists.
For more information on the AAPM&R Annual Assembly and the academy, visit www.aapmr.org.
About Ekso Bionics®
Ekso Bionics® is a leading developer of exoskeleton solutions that amplify human potential by supporting or enhancing strength, endurance and mobility across medical, industrial and defense applications. Founded in 2005, the company continues to build upon its unparalleled expertise to design some of the most cutting-edge, innovative wearable robots available on the market. Ekso Bionics is the only exoskeleton company to offer technologies that range from helping those with paralysis to stand up and walk, to enhancing human capabilities on job sites across the globe, to providing research for the advancement of R&D projects intended to benefit U.S. defense capabilities. The company is headquartered in the Bay Area and is listed on the Nasdaq Capital Market under the symbol EKSO. For more information, visit: www.eksobionics.com.
About EksoGT™
EksoGT™ is the first exoskeleton cleared by the FDA for use with stroke and spinal cord injuries from L5 to C7. The EksoGT with SmartAssist™ software is the only exoskeleton available for rehabilitation institutions that can provide adaptive amounts of power to either side of a patient's body, challenging the patient as they progress through their continuum of care. The suit's patented technology provides the ability to mobilize patients earlier, more frequently, and with a greater number of high intensity steps. To date, this device has helped patients take more than 80 million steps in over 185 rehabilitation institutions around the world.
Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of human exoskeletons, (ii) estimates or projection of financial results, financial condition, capital expenditures, capital structure or other financial items, (iii) the Company's future financial performance and (iv) the assumptions underlying or relating to any statement described in points (i), (ii) or (iii) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain adequate financing to fund the Company's operations and necessary to develop or enhance our technology, the significant length of time and resources associated with the development of the Company's products, the Company's failure to achieve broad market acceptance of the Company's products, the failure of our sales and marketing organization or partners to market our products effectively, adverse results in future clinical studies of the Company's medical device products, the failure to obtain or maintain patent protection for the Company's technology, failure to obtain or maintain regulatory approval to market the Company's medical devices, lack of product diversification, existing or increased competition, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. To learn more about Ekso Bionics please visit us at www.eksobionics.com. The Company does not undertake to update these forward-looking statements.
Media Contact:
Carrie Yamond
917-371-2320
cyamond@lazarpartners.com
Investor Contact:
David Carey
212-867-1768
investors@eksobionics.com
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
